About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingNANCT06483308

Shortened High-dose Palliative Radiotherapy for Lung Cancer

The SHiP-Rt Study aims to investigate the safety and efficacy of reducing the number of RT fractions and RT duration, compared to the current standard of care (36Gy in 12 fractions over 16 days), by u...

Lead sponsor: University Hospitals Coventry and Warwickshire NHS Trust•4 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Hospitals Coventry and Warwickshire NHS Trust

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age ≥ 18
•Patient has locally advanced (stage IIIB or IIIC) or metastatic (stage IV) NSCLC
•Patient is treatment naïve or had limited progression after first-line systemic therapy (using chemotherapy, immunotherapy, or targeted therapy)
•Patient is suitable for high dose palliative RT (36Gy in 12# or 39Gy in 13#)
•Obtained written informed consent for the SHiP-Rt study.
•Patients receiving RT after first-line systemic therapy must have a wash-out period of at least 3 weeks (i.e., 3-4 weeks).
•Treatment naïve patients should be able to proceed to definitive systemic therapy without undue delay, i.e., within 3-4 weeks.

Exclusion Criteria

•Contraindication for thoracic RT
•Requiring lung RT after second-line systemic therapy for NSCLC
•Has more than 1 cancer that is requiring active treatment
•On cytotoxic treatment for rheumatoid arthritis or connective tissue disorders
•Poor life expectancy, likely less than 6 months
•Patients with difficulty regarding compliance to the study treatment or follow-up
•Previous radiotherapy to the same area

Related studies

RECRUITINGPhase 3

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

RECRUITINGPhase 1/2

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

NCT06287775 · Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

RECRUITINGPhase 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

NCT04771520 · Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, and more

RECRUITINGPhase 3

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06500455 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

RECRUITINGPhase 2

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

NCT07288034 · Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 13, 2026Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhaseNA

Enrollment37

Start dateNov 2024

Last updatedApr 13, 2026

Condition

Stage IV Lung Cancer

Locations shown

University Hospitals of North Midlands NHS Trust

Stoke-on-Trent, Staffordshire

University Hospitals Coventry and Warwickshire

Coventry, Warwickshire

University Hospitals Birmingham NHS Foundation Trust

Birmingham, West Midlands

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 13, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions